COVID-19 Causes 67% of Experts to use Decentralized Trials in Future, says GlobalData
Healthcare experts have noted that their number one primary concern amid the COVID-19 pandemic was the delay to initiation or inability to conduct clinical trials, according to a recent survey by GlobalData. The data and analytics company notes that at peak over 1,200 clinical trials experienced some level of delay due to the COVID-19 pandemic.
The survey, completed between June 4th-22th, found remote patient monitoring and shifting towards the use of decentralized clinical trials were the top two methods respondents are using to address disruptions. Out of 150 respondents, only 34% were already using decentralized clinical trials, most located in North America. Contract service providers were the biggest current adopters.
Furthermore, according to 67% of survey participants, COVID-19 is the reason they plan to use decentralized clinical trials in the future.
Read the full release and get more of the findings, here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
